Who
Christophe Arbet-Engels
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Altimmune; Chief Medical Officer, X4 Pharmaceuticals; Chief Medical Officer, Tempest Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $5,231
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 10 Feb 2020
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $35K12,679 at $2.76 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
| 24 Jan 2025filed 27 Jan 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,23111,624 at $0.45 | filing |
| 23 Jan 2025filed 27 Jan 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,831 at $0.00 | filing |
| 13 Feb 2024filed 28 Feb 2024 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,816 at $0.00 | filing |
| 13 Feb 2024filed 16 Feb 2024 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,831 at $0.00 | filing |
| 31 Aug 2023filed 5 Sep 2023 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.6M1,250,000 at $1.28 | filing |
| 25 May 2020filed 27 May 2020 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 10 Feb 2020filed 11 Feb 2020 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.